Amgen, Inc. (AMGN) Tops Q3 EPS by 20c; Boosts FY12 Outlook
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $374.15 +3.55%
Revenue Growth %: +2.6%
Financial Fact:
Interest expense, net: 325M
Today's EPS Names:
CRMT, More
Revenue Growth %: +2.6%
Financial Fact:
Interest expense, net: 325M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Amgen, Inc. (NASDAQ: AMGN) reported Q3 EPS of $1.67, $0.20 better than the analyst estimate of $1.47. Revenue for the quarter came in at $4.32 billion versus the consensus estimate of $4.25 billion.
Amgen, Inc. sees FY2012 EPS of $6.50-6.60, versus the consensus of $6.35. Amgen, Inc. sees FY2012 revenue of $17.2-17.3 million, versus the consensus of $17.04 million.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
Amgen, Inc. sees FY2012 EPS of $6.50-6.60, versus the consensus of $6.35. Amgen, Inc. sees FY2012 revenue of $17.2-17.3 million, versus the consensus of $17.04 million.
For earnings history and earnings-related data on Amgen, Inc. (AMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Six Flags names Mark Pauls as chief operating officer
- SAS CEO van der Werff emerges as frontrunner for Air Canada top job - Bloomberg
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
